Transcriptomics

Dataset Information

0

Group 3 medulloblastomatranscriptional networks collapse under domain-specific EP300/CBP inhibition.


ABSTRACT: EP300 and CBP are paralogous, multidomain histone acetyltransferases (HATs) that regulate gene expression by binding to and acetylating diverse proteins. With widespread effects on gene regulation, these enzymes are attractive targets for therapeutic development. Discovery efforts for chemical inhibitors typically target protein domains that are amenable to probe binding. In some cases, probes have been identified for more than one domain within a single protein, including high potency inhibitors of both the catalytic HAT domain and bromodomain (BRD) that mediate the enzymatic and protein binding (“reader”) activities of EP300/CBP. In cancer cell systems, combination inhibition of both domains is more toxic than single inhibitor alone, indicating that inhibition of individual domain functions may elicit differential effects. Thus, we hypothesized that determining the relative effects of domain-specific inhibition of EP300/CBP on tumor cell growth may elucidate exceptional-responding tumor types to one inhibitor or the other. This would permit a broader therapeutic index by enabling reduced dosing of domain-targeted inhibitors, while maintaining enhanced inhibition of cancer cell growth. Here, using high-throughput cell line-based screening, we demonstrate that targeting the HAT or BRD domains of EP300/CBP using the chemical probes A485 and CCS1477 has differential effects in select tumor types. Group 3 medulloblastoma (G3MB) cells were especially sensitive to EP300/CBP BRD inhibition, as compared with HAT inhibition. Structurally, these effects are mediated by the difluorophenyl group in the catalytic core of CCS1477. Mechanistically, the effects of bromodomain and HAT-domain specific inhibition are distinct, with bromodomain inhibition causing rapid early disruption of genetic dependency networks that are required for G3MB growth. These studies provide a domain-specific structural foundation for drug discovery efforts targeting EP300/CBP and identify a selective role for the EP300/CBP bromodomain in maintaining genetic dependency networks in G3MB cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE233609 | GEO | 2024/02/23

REPOSITORIES: GEO

Similar Datasets

2016-01-05 | E-GEOD-64317 | biostudies-arrayexpress
2016-01-05 | E-GEOD-71909 | biostudies-arrayexpress
2016-01-05 | GSE71909 | GEO
2016-01-05 | GSE64317 | GEO
2019-02-14 | GSE124582 | GEO
2019-02-14 | GSE124581 | GEO
2019-02-14 | GSE118218 | GEO
2023-08-07 | GSE193647 | GEO
2023-08-07 | GSE193646 | GEO
2023-08-07 | GSE193645 | GEO